Nail psoriasis and biologics

Journal of Cutaneous Medicine and Surgery

Volumn 13, Issue 1, 2009, Pages 1-5

  Noiles, Kristin ^a,b   Vender, Ronald ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; PLACEBO; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

CLINICAL TRIAL; DISEASE CONTROL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; EVIDENCE BASED PRACTICE; HUMAN; MEDLINE; NAIL BED; NAIL DISEASE; NAIL PSORIASIS; PRIORITY JOURNAL; PSORIASIS; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; NAIL DISEASES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS;

EID: 64849102147     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2008.08012     Document Type: Review

References (23)

1. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598-606.
2. Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica 1974;148:1-18.
3. Rich P, Griffiths CEM, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008;58:224-31.
4. Scher RK. Psoriasis of the nail. Dermatol Clin 1985;3:387-94.
5. Scarpa R, Oriente P, Pucino A, et al. Psoriatic arthritis in psoriatic patients. Br J Rheum 1984;23:246-50.
6. Lavaroni G, Kokelj F, Pauluzzi P, et al. The nails in psoriatic arthritis. Acta Derm Venereol 1994;186 113.
7. Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: nail disease in psoriatic arthritis - clinically important, potentially treatable and often overlooked. Rheumatology 2004;43:790-4.
8. de Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology 1996;193:300-3.
9. Lamerson C, Stevens G, Sax K. Treatment of nail psoriasis with efalizumab. Presented at the Summer American Academy of Dermatology (AAD) 2006; San Diego.
10. van den Bosch F, Reece R, Behrens F, et al. Clinically important nail psoriasis imrpovements are achieved with adalimumab (HUMIRA): results from a large open-label prospective study (STEREO). Presented at the EULAR annual scientific meeting; EULAR 2007: The Annual European Congress of Rheumatology; Barcelona, Spain, 2007.
11. Rich P, Scher R. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49:206-12.
12. Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007;57: 1-27.
13. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74.
14. Bianchi L, Bergamin A, de Felice C, et al. Remission and time of resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol 2005;52:736-7.
15. de Rie M, Giannetti A, Walker S, et al. Nail psoriasis improves after 12 weeks of etanercept therapy in patients with moderate to severe psoriasis. Presented at the 16th Congress of the European Academy of Dermatology & Venereology; Vienna, Austria. 2007.
16. Rich P, Gupta A, Wang A, et al. Etanercept improves nail psoriasis. Presented at the Canadian Dermatology Association 80th Annual Conference; Québec City; 2005.
17. Rich P. Efficacy and safety of efalizumab for nail psoriasis: results of an open-label, multicenter study. Presented at the American Academy of Dermatology annual meeting 2008 February 1-5; San Antonio, TX.
18. Martins G, Stengel F, Allevato M, et al. Efalizumab improves nail psoriasis symptoms: results from a phase IIIB/IV clinical trial in patients from Latin American countries with moderate-to-severe plaque psoriasis. Presented at the 21st World Congress of Dermatology; 2007 September 30-October 5; Buenos Aires, Argentina.
19. Cassety CT, Alexis AF, Shupack JL, et al. Alefacept in the treatment of psoriatic nail disease. Presented at the 62nd annual meeting of the American Academy of Dermatology; 2005 February 6-11; Washington, DC.
20. Cassety CT, Alexis AF, Shupack JL, et al. Alefacept in the treatment of psoriatic nail disease: a small case series [letter]. J Am Acad Dermatol 2005;52:1101-2.
21. Parrish CA, Sobera JO, Robbins CM, et al. Alefacept in the treatment of psoriatic nail disease: a proof of concept study. J Drugs Dermatol 2006;5:339-40.
22. Papoutsaki M, Chimenti MS, Costanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open label study in 30 patients previously treated with other biologics. J Am Acad Dematol 2007;57:269-75.
23. Gisondi P, Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. J Autoimmun Rev 2000;6:515-9.